Initial Management of Diabetes in Hospitalized Patients with Urinary Infection

Introduction to Diabetes Management

The American College of Physicians recommends initiating metformin as the first-line pharmacological agent, along with lifestyle modifications, in patients with newly diagnosed diabetes, without severe hyperglycemia, and who are clinically stable 1, 2
The American Diabetes Association suggests that metformin is the preferred initial pharmacological agent for patients who meet specific criteria for oral monotherapy, including HbA1c <8.5%, glucose <250 mg/dL, and being asymptomatic metabolically 1, 2, 3

The American College of Physicians states that metformin has proven efficacy, low cost, an established safety profile, and can reduce cardiovascular events and mortality 2
The American Diabetes Association notes that metformin has been shown to reduce HbA1c by an average of 1.4% and fasting glucose by 53 mg/dL in controlled studies 2

The American College of Physicians recommends starting metformin at 500 mg once daily with dinner for 1 week, then titrating to 500 mg twice daily, and eventually to 850 mg twice daily if tolerated, with a maximum effective dose of 1000 mg twice daily 2

The American College of Physicians advises verifying renal function before initiating metformin, which can be used with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m², although dose reduction is required with an eGFR of 30-45 mL/min/1.73 m² 2
The American Diabetes Association recommends suspending metformin temporarily during hospitalization if the patient requires intravenous contrast studies, develops sepsis or hemodynamic deterioration, or experiences renal function deterioration (eGFR <30 mL/min/1.73 m²) 1, 2, 3

The American College of Physicians states that insulin is not indicated at this time because the patient does not meet any of the following criteria: glucose ≥250 mg/dL with symptoms, HbA1c ≥8.5-9%, ketosis or ketoacidosis, severe hyperglycemia (≥300-350 mg/dL), or metabolic instability 1, 2, 4, 5

The American Diabetes Association recommends implementing lifestyle changes simultaneously with metformin, including a weight loss goal of 5-10% of body weight if overweight or obese, at least 150 minutes/week of moderate-intensity physical activity, and a diet emphasizing fiber-rich foods, low-fat dairy products, and fresh fish, while limiting saturated fats and sugary desserts 2, 5

The American Diabetes Association suggests a glycemic target of HbA1c <7% for this patient, considering the absence of severe limiting comorbidities, no history of severe hypoglycemia, reasonable life expectancy, and the potential to prevent microvascular complications 3, 5
The American College of Physicians recommends monitoring HbA1c every 3 months until the target is reached, then every 6 months, as well as performing capillary glucose measurements initially and assessing renal function at the start and annually 1, 2

The American College of Physicians advises that the consultation with Internal Medicine should focus on evaluating comorbidities, screening for microvascular complications, optimizing cardiovascular risk factors, providing structured diabetes education, and establishing a long-term follow-up plan 1, 3, 5

The American College of Physicians recommends that if after 3 months of metformin at the maximum tolerated dose the HbA1c remains >7%, a second agent should be added, with options including DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists, sulfonylureas, or basal insulin, depending on patient characteristics 1, 2
The American Diabetes Association suggests considering basal insulin if HbA1c >9% at any time, or if there is failure to metformin plus a second oral agent, or if there is a contraindication or intolerance to metformin 1, 2